Evidence map›Paper›PMID 33586340›Full record

ArticleJournal of cachexia, sarcopenia and muscle2021

Myogenesis modelled by human pluripotent stem cells: a multi-omic study of Duchenne myopathy early onset.

Virginie Mournetas, Emmanuelle Massouridès, Jean-Baptiste Dupont, Etienne Kornobis, Hélène Polvèche, Margot Jarrige, Alan R L Dorval, Maxime R F Gosselin, Antigoni Manousopoulou, Spiros D Garbis and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of cachexia, sarcopenia and muscle, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 59 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 4 countries.

Virginie MournetasINSERM UEVE UMR861, I-STEM, AFM, Corbeil-Essonnes, France.ORCID 0000-0002-6557-4190
Emmanuelle MassouridèsCECS, I-STEM, AFM, Corbeil-Essonnes, France.ORCID 0000-0002-9829-5008
Jean-Baptiste DupontINSERM UEVE UMR861, I-STEM, AFM, Corbeil-Essonnes, France.ORCID 0000-0001-5706-8178
Etienne KornobisBiomics, C2RT, Institut Pasteur, Paris, France.ORCID 0000-0001-7712-8270
Hélène PolvècheCECS, I-STEM, AFM, Corbeil-Essonnes, France.ORCID 0000-0002-5601-3498
Margot JarrigeCECS, I-STEM, AFM, Corbeil-Essonnes, France.ORCID 0000-0002-5877-2615
Alan R L DorvalCECS, I-STEM, AFM, Corbeil-Essonnes, France.ORCID 0000-0001-6783-5772
Maxime R F GosselinMolecular Medicine, School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK.ORCID 0000-0002-8916-0953
Antigoni ManousopoulouDepartment of Immuno-Oncology, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA.ORCID 0000-0001-5028-1865
Spiros D GarbisUnit for Cancer Sciences, Centre for Proteomics Research, Institute for Life Sciences, University of Southampton, Southampton, UK.ORCID 0000-0002-1050-0805
Dariusz C GóreckiMolecular Medicine, School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK.ORCID 0000-0003-3584-1654
Christian PinsetCNRS, I-STEM, AFM, Corbeil-Essonnes, France.ORCID 0000-0002-7840-2179
Institut des Cellules Souches pour le Traitement et l'Étude des Maladies Monogéniques · FRInserm · FRCentre National de la Recherche Scientifique · FRCity Of Hope National Medical Center · USInstitut Pasteur · FRPath BioAnalytics (United States) · USUniversity of Portsmouth · GBWojskowy Instytut Higieny i Epidemiologii · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDuchenne muscular dystrophy (DMD) causes severe disability of children and death of young men, with an incidence of approximately 1/5000 male births. Symptoms appear in early childhood, with a diagnosis made mostly around 4 years old, a time where the amount of muscle damage is already significant, preventing early therapeutic interventions that could be more efficient at halting disease progression. In the meantime, the precise moment at which disease phenotypes arise-even asymptomatically-is still unknown. Thus, there is a critical need to better define DMD onset as well as its first manifestations, which could help identify early disease biomarkers and novel therapeutic targets.

methodsWe have used both human tissue-derived myoblasts and human induced pluripotent stem cells (hiPSCs) from DMD patients to model skeletal myogenesis and compared their differentiation dynamics with that of healthy control cells by a comprehensive multi-omic analysis at seven time points. Results were strengthened with the analysis of isogenic CRISPR-edited human embryonic stem cells and through comparisons against published transcriptomic and proteomic datasets from human DMD muscles. The study was completed with DMD knockdown/rescue experiments in hiPSC-derived skeletal muscle progenitor cells and adenosine triphosphate measurement in hiPSC-derived myotubes.

resultsTranscriptome and miRnome comparisons combined with protein analyses demonstrated that hiPSC differentiation (i) leads to embryonic/foetal myotubes that mimic described DMD phenotypes at the differentiation endpoint and (ii) homogeneously and robustly recapitulates key developmental steps-mesoderm, somite, and skeletal muscle. Starting at the somite stage, DMD dysregulations concerned almost 10% of the transcriptome. These include mitochondrial genes whose dysregulations escalate during differentiation. We also describe fibrosis as an intrinsic feature of DMD skeletal muscle cells that begins early during myogenesis. All the omics data are available online for exploration through a graphical interface at https://muscle-dmd.omics.ovh/.

conclusionsOur data argue for an early developmental manifestation of DMD whose onset is triggered before the entry into the skeletal muscle compartment, data leading to a necessary reconsideration of dystrophin roles during muscle development. This hiPSC model of skeletal muscle differentiation offers the possibility to explore these functions as well as find earlier DMD biomarkers and therapeutic targets.

Indexed as

Muscle DevelopmentMuscular Dystrophy, DuchenneDystrophinHumansInduced Pluripotent Stem CellsMaleProteomicsDystrophinDuchenne muscular dystrophyHuman pluripotent stem cellsMyogenesisOmics

Identifiers

PMID33586340
PMCPMC7890274
OpenAlexW3132184986

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.